Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States
Real-world evidence suggests multimorbidity among tirzepatide initiators, slower tirzepatide dose escalation than in clinical trials, and clinically meaningful weight reduction among people persisting on tirzepatide for ≥ 6 months.
Authors
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Donna Mojdami
- Chanadda Chinthammit (ORCID: https://orcid.org/0000-0002-3469-1327)
- Cachet Wenziger
- Emily R. Hankosky (ORCID: https://orcid.org/0000-0001-9934-584X)
- Grace Stockbower
- Michael Grabner (ORCID: https://orcid.org/0000-0002-6521-1007)
- Xuanyao He
- Karishma Desai (ORCID: https://orcid.org/0000-0001-6108-4154)
Institutions
- Eli Lilly (United States) (US)
- Wilmington University (US)
Publication Details
- Journal
- Diabetes & Metabolism
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.diabet.2025.101636
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36
Funders
- Eli Lilly and Company